Navigation Links
Researchers Make Headway in Treatment of Diabetic Retinopathy

Research has shown a way for people suffering diabetic retinopathy. The treatment envisaged assists in retarding as well as alleviating the effects of diabetic retinopathy,// which is by far the most common consequence of diabetes.

In the initial stages, retinopathy does not portray any visible symptoms but is capable of progressing gradually to cause the blood vessels of the eye to leak and break easily which ultimately could cause blindness. This complication is triggered by high blood glucose levels, almost all people suffering type 1 diabetes portray few symptoms of the disorder.

An in-depth article in the spring 2007 edition of Countdown, the quarterly journal of the Juvenile Diabetes Research Foundation, details ongoing human clinical trials in this area, and important findings that have been made to date. In the article, JDRF-funded scientists share valuable insights into the causes of retinopathy, as well as the therapeutics that are being developed as a result of the identification of new biological targets.

One study mentioned within the article was led by Dr. Lloyd Aiello of the Joslin Diabetes Center, who showed that the compound ruboxistaurin slowed the progress of retinopathy by inhibiting an enzyme in the body called protein kinase C beta (PKC beta), which is believed to contribute to the blood vessel damage that leads to the disease. This is the first time a drug has been shown to protect against the complication in a human clinical trial.

According to Dr. Richard Insel, Executive Vice President of Research for JDRF, "Since retinopathy is the most common and serious eye-related complication of those with type 1 and type 2 diabetes – and is the leading cause of adult blindness in Americans – the outstanding research being done in this area will have a significant impact on the millions of people with diabetes."

Source-Eurekalert/
'"/>




Page: 1

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2017)... KOREA (PRWEB) , ... July ... ... receipt of CE marking for its faster PICOPLUS 450 ps pulse width ... picosecond- and nanosecond-domain 1,064-nm neodymium-doped yttrium-aluminum-garnet lasers in tissue-mimicking phantom’ featured in ...
(Date:7/17/2017)... ... July 17, 2017 , ... Summer camp season ... to ensure children are protected from Lyme and other tick-borne diseases. , With ... an increased risk not only for the tick-borne illness, but for its various ...
(Date:7/17/2017)... ... July 17, 2017 , ... HMP , a ... with the Texas Academy of Family Physicians (TAFP) for the 6th ... at the Hyatt Regency Dallas in Dallas, Texas.     , CRS and TAFP will ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
(Date:7/17/2017)... Aliso Viejo, CA (PRWEB) , ... July 17, 2017 , ... ... Pro X. These minimalistic layouts can be used to complement vlogs, professional productions, and ... using the click of a mouse. Manipulate camera controls to make beautiful and unique ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... June 30, 2017  AVACEN Medical (AVACEN) announced the publication of ... describes the use of its AVACEN Treatment Method to ... fibromyalgia. ... AVACEN Medical ... chronic widespread pain. It affects approximately 200 to 400 million people worldwide ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... Netherlands and LAGUNA HILLS, Calif. ... the presentation of new data that validate the use ... risk stratify patients with multiple myeloma (MM). In a ... the European Hematology Association (EHA) in Madrid, ... value of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: